ERBB2 and cancer: HER2 gene amplification was first associated with worse clinical outcomes in the late 1980s by Slamon et al., and the following series of studies revealed that residents of the Asia-Pacific areas were associated with high occurrence rate HER2-positive cancer with a poorer prognosis in comparison with other regions [23–25].